Side Effects: There were no serious incidents of hypoglycaemia (too little blood sugar) reported, nor were there any maglinancies in the thyroid gland or reports persistent hyperglycaemia (too much blood sugar) 8% of patients across all Retatrutide groups collectively did not continue treatment because of an adverse event The most commonly reported adverse events in people taking Retatrutide were gastrointestinal in nature (constipation, diarrhea, vomiting, nasuea), were mild to moderate in severity, and happened more often in people taking larger doses of Retatrutide All in all, patients on Retatrutide experienced a dramatic improvement in insulin sensitivity and any observed side effects were not significantly different in severity, type or frequency compared to the Phase 2 trial for obesity
Patients who monitor only weight and ignore blood sugar, blood pressure, lipid levels, and inflammatory markers miss important signals about when to continue, taper, or adjust treatment
You can benefit from retatrutide therapy if: You are obese (BMI 30 kg/m or more) or overweight (BMI 27 kg/m or more) with at least one weight-related health condition
Use code JayC to get 15% off your order
